Last reviewed · How we verify
Université du Québec à Trois-Rivières — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Saline Solution (NaCl 0,9%) | Saline Solution (NaCl 0,9%) | marketed | Crystalloid fluid / Electrolyte replacement | Fluid and Electrolyte Management |
Therapeutic area mix
- Fluid and Electrolyte Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Dalarna County Council, Sweden · 1 shared drug class
- Fundacion Clinica Valle del Lili · 1 shared drug class
- Montefiore Medical Center · 1 shared drug class
- Rhode Island Hospital · 1 shared drug class
- Rigshospitalet, Denmark · 1 shared drug class
- Seoul National University Hospital · 1 shared drug class
- Universidad Nacional de La Plata · 1 shared drug class
- University of Auckland, New Zealand · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Université du Québec à Trois-Rivières:
- Université du Québec à Trois-Rivières pipeline updates — RSS
- Université du Québec à Trois-Rivières pipeline updates — Atom
- Université du Québec à Trois-Rivières pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Université du Québec à Trois-Rivières — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universit-du-qu-bec-trois-rivi-res. Accessed 2026-05-18.